Prevention of postmenopausal osteoporosis. Part 1: Identification of patients at risk and nonhormone preventive measures

被引:0
|
作者
Birkhaeuser, M. [1 ]
机构
[1] Univ Bern, Bern, Switzerland
来源
GYNAKOLOGISCHE ENDOKRINOLOGIE | 2013年 / 11卷 / 02期
关键词
Vitamin D; Calcium; Physical exercise; Risk factors; Fracture risk;
D O I
10.1007/s10304-013-0550-x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background. Osteoporosis is one of the most frequent and cost-intensive diseases. In women aged >50 years and in postmenopausal women of all ages suffering from malnutrition or having an insufficient exposition to sunlight leading to low serum vitamin D levels, an adequate calcium intake, a sufficiently high vitamin D supplementation increasing with age and a sufficient protein intake (minimally 1 g/kg body weight protein per day) are essential for primary prevention of osteoporotic fractures. Vitamin D supplementation. Vitamin D prevents fractures through two mechanisms. Vitamin D has a positive effect on bone metabolism, and vitamin D increases muscle strength, resulting in a decreased risk of falls. Some sources recommend a vitamin D intake of 800-1000 IU/day. However, others suggest 1500-2000 IU/day vitamin D for adults aged >19 years. In the elderly having a high fracture risk, up to 2000 IU vitamin D/day is recommended. Calcium supplements. The preventive effect of vitamin D implies a sufficient, but not excessive daily calcium intake. To prevent osteoporotic fractures, a preferentially alimentary calcium supplementation of 1000-1200 mg/day calcium is recommended. The efficiency and safety of an adequate calcium and vitamin D supplementation has been proven. In particular, in studies observing the calcium intake limits defined above, no increased cardiovascular risk was observed. Uncontrolled additional calcium intake is not indicated. General measures. General prevention includes regular physical exercise (including strength training) combined with equilibrium training to prevent falls. Risk factors such as cigarette smoking, excessive alcohol intake and-if possible-the intake of drugs having a negative impact on bone metabolism (e.g., glucocorticoids, antiepileptics, suppressive thyroid hormone therapy) should be avoided. General preventive measures can be recommended without specific diagnostic investigations. Each therapeutic decision has to be preceded by an appropriate investigation for osteoporosis and prevalent fractures
引用
收藏
页码:129 / 136
页数:8
相关论文
共 50 条
  • [21] Performance of simple risk indices for identifying postmenopausal Japanese women with osteoporosis.
    Fujiwara, S
    Masunari, N
    Suzuki, G
    Ross, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S341 - S341
  • [22] Demystifying the Risk Factors and Preventive Measures for Osteoporosis
    Vaishya, Raju
    Iyengar, Karthikeyan P.
    Jain, Vijay Kumar
    Vaish, Abhishek
    INDIAN JOURNAL OF ORTHOPAEDICS, 2023, 57 (SUPPL 1) : 94 - 104
  • [23] Strontium ranelate reduces the vertebral fracture risk in women with postmenopausal osteoporosis.
    Meunier, PJ
    Roux, C
    Ortolani, S
    Badurski, J
    Kaufman, JM
    Spector, T
    Diez-Perez, A
    Seeman, E
    Lemmel, E
    Balogh, A
    Pors-Nielsen, S
    Phenekos, C
    Rizzoli, R
    Slosman, D
    Tupinon-Mathieu, I
    Reginster, JY
    OSTEOPOROSIS INTERNATIONAL, 2002, 13 (06) : 521 - 522
  • [24] Diagnostic efficiency of a self-evaluating risk assessment for postmenopausal osteoporosis.
    Goemaere, S
    Zegels, B
    Toye, K
    Cremer, S
    Demuynck, R
    Vanheusden, E
    Albert, A
    Dewe, W
    Kaufman, JM
    Reginster, JY
    JOURNAL OF BONE AND MINERAL RESEARCH, 1997, 12 : S570 - S570
  • [25] Effect of risedronate therapy on serum osteoprotegerin levels in patients with postmenopausal osteoporosis.
    Baek, KH
    Tae, HJ
    Han, JH
    Kang, MI
    Lee, WY
    Oh, KW
    Lee, KW
    Cho, CS
    JOURNAL OF BONE AND MINERAL RESEARCH, 2004, 19 : S309 - S309
  • [26] Denosumab for Prevention of Fractures in Postmenopausal Women with Osteoporosis. (vol 361, pg 756, 2009)
    Cummings, S. R.
    San Martin, J.
    McClung, M. R.
    Siris, E. S.
    Eastell, R.
    Reid, I. R.
    Delmas, P.
    Zoog, H. B.
    Austin, M.
    Wang, A.
    Kutilek, S.
    Adami, S.
    Zanchetta, J.
    Libanati, C.
    Siddhanti, S.
    Christiansen, C.
    NEW ENGLAND JOURNAL OF MEDICINE, 2009, 361 (19): : 1914 - 1914
  • [27] Risedronate reduced the risk of nonvertebral fractures as soon as 6 months in postmenopausal osteoporosis.
    Brandi, ML
    Harrington, TJ
    Barton, I
    Ste-Marie, LG
    JOURNAL OF BONE AND MINERAL RESEARCH, 2002, 17 : S270 - S270
  • [28] Testing and validation of simple clinical risk indices to identify postmenopausal women with osteoporosis.
    Hochberg, MC
    Thompson, DE
    Ross, PD
    JOURNAL OF BONE AND MINERAL RESEARCH, 2001, 16 : S277 - S277
  • [29] Oral clodronate significantly reduces fracture risk in women with postmenopausal or secondary osteoporosis.
    McCloskey, EV
    Selby, P
    Davies, M
    Francis, R
    Robinson, J
    Kayan, K
    Beneton, M
    Jalava, T
    Pylkkanen, L
    Kenrali, J
    Kanis, J
    JOURNAL OF BONE AND MINERAL RESEARCH, 2000, 15 : S227 - S227
  • [30] Alcohol consumption and the risk of fractures in male patients with osteoporosis.
    Lazarescu, AD
    Lazarescu, D
    Pfeifer, M
    Polahne, W
    Minne, HW
    JOURNAL OF BONE AND MINERAL RESEARCH, 1996, 11 : S530 - S530